Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology, Inc. filings document the regulatory record for a public biotechnology company developing engineered-cell medicines. Recent 8-K reports disclose operating results, corporate presentations, program updates for UP421, SC451, and SG293, at-the-market common stock sales arrangements, executive appointments, and board-class governance matters.
Proxy materials describe annual meeting voting items, director elections, board structure, executive compensation, and stockholder governance procedures. The company’s filings also capture material agreements, capital-structure disclosures, Regulation FD presentations, and other event reports tied to its cell-therapy pipeline and public-company obligations.
Sana Biotechnology director Patrick Y. Yang received a new stock option grant, giving him the right to acquire 90,000 shares of common stock at an exercise price of $2.96 per share. The option vests in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, as long as he continues providing service to the company. Following this award, he holds 90,000 derivative securities linked to Sana common stock directly.
Sana Biotechnology director Robert L. Rosiello received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming he remains in continuous service.
Sana Biotechnology director Michelle Seitz received a grant of stock options for 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest and become fully exercisable on the earlier of June 4, 2027 or immediately prior to Sana’s 2027 annual stockholder meeting, as long as she continues to provide service to the company through that date. Following this award, she holds 90,000 stock options directly, reflecting a compensation-related acquisition rather than an open-market share purchase.
Sana Biotechnology director Alise Reicin received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and will expire on June 3, 2036.
The option vests in full as to all 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana Biotechnology’s 2027 annual meeting of stockholders, as long as Reicin continues providing service to the company through that date. Following this grant, she holds options on 90,000 shares directly.
Sana Biotechnology director Richard Mulligan received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholders’ meeting, if he continues serving the company. Following this grant, he holds 90,000 options directly.
Sana Biotechnology, Inc. director Hans Edgar Bishop received a grant of stock options covering 90,000 shares of Common Stock at an exercise price of $2.96 per share. Following this grant, he holds options on 90,000 shares directly.
The options vest and become exercisable for all 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual meeting of stockholders, provided he continues to serve the company through that date.
Sana Biotechnology, Inc. director Joshua H. Bilenker received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.9600 per share and expire on June 3, 2036.
These options vest and become exercisable in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual meeting of stockholders, provided he continues to serve the company through that date. Following this grant, he holds 90,000 derivative securities directly.
Sana Biotechnology director Robert Nelsen received a grant of stock options covering 90,000 shares of Common Stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming continuous service. Following this grant, Nelsen holds options for 90,000 shares directly.
Sana Biotechnology, Inc. reported the results of its 2026 annual meeting of stockholders held on June 4, 2026. Stockholders elected three Class II directors to three-year terms expiring at the 2029 annual meeting. Hans E. Bishop received 117,452,573 votes for and 57,148,432 withheld, Robert Nelsen received 160,384,193 votes for and 14,216,812 withheld, and Alise S. Reicin, M.D. received 149,865,546 votes for and 24,735,459 withheld, with 30,606,441 broker non-votes recorded for each nominee.
Stockholders also ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 203,932,500 votes for, 831,419 against, and 443,527 abstentions.
RA Capital Management and affiliated filers reported beneficial ownership of 18,750,000 shares of Sana Biotechnology common stock in a joint Schedule 13G filing. The filing states this equals 6.3% of the class based on 278,291,590 shares outstanding as of April 30, 2026 and an additional 21,607,878 shares issued under an at-the-market offering as of May 14, 2026.
The Fund directly holds the reported shares and RA Capital, Dr. Peter Kolchinsky and Rajeev Shah disclose shared voting and dispositive power through advisory and general partner relationships; the filing includes standard disclaimers about beneficial ownership attribution.